In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Home Diagnostics nets $48.7mm with IPO

Executive Summary

Home Diagnostics Inc. (HDI), a company that specializes in diabetes management, netted $48.7mm in its initial public offering of 4.3mm common shares (including the overallotment) at $12 apiece. In May, it originally hoped to sell up to $115mm, and in July it changed the estimate to 3.3mm shares at $14-16. Shareholders also sold some of their stock in the IPO.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies